Lipocine (LPCN) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Lipocine (LPCN) has outperformed Rocket One (RKTO) over the past year, losing 45.4% versus a loss of 61.1%. Over five years, LPCN leads with a -91.0% price change compared with -97.8% for RKTO. Rocket One is the larger company by market cap ($16.2 million vs $14.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LPCN | RKTO |
|---|---|---|
| Share price | $1.72 | $0.6493 |
| Market cap | $14.18M | $16.17M |
| 1-day change | -10.88% | +0.50% |
| YTD return | -78.58% | -34.41% |
| 1-year return | -45.40% | -61.12% |
| 5-year return | -91.05% | -97.76% |
| EPS (TTM) | $-1.65 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.37 | $2.45 |
| 52-week low | $1.72 | $0.489 |
| Distance from 52-week high | -86.10% | -73.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +190.70% | — |
| Average volume | 1.75M | 554.01K |
| Shares outstanding | 8.24M | 24.90M |
| Employees | 14 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed RKTO by 15.7 percentage points over the past year.
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
LPCN vs RKTO FAQ
Which is bigger, Lipocine or Rocket One?
Rocket One (RKTO) is larger, with a market capitalization of $16.17M compared with $14.18M for Lipocine (LPCN).
Which stock has performed better over the past year, LPCN or RKTO?
LPCN returned -45.40% over the past 12 months, compared with -61.12% for RKTO (price return, excluding dividends). Past performance does not predict future results.
Are Lipocine and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.